Literature DB >> 10590124

Adenovirus vector pseudotyping in fiber-expressing cell lines: improved transduction of Epstein-Barr virus-transformed B cells.

D J Von Seggern1, S Huang, S K Fleck, S C Stevenson, G R Nemerow.   

Abstract

While adenovirus (Ad) gene delivery vectors are useful in many gene therapy applications, their broad tropism means that they cannot be directed to a specific target cell. There are also a number of cell types involved in human disease which are not transducible with standard Ad vectors, such as Epstein-Barr virus (EBV)-transformed B lymphocytes. Adenovirus binds to host cells via the viral fiber protein, and Ad vectors have previously been retargeted by modifying the fiber gene on the viral chromosome. This requires that the modified fiber be able to bind to the cell in which the vector is grown, which prevents truly specific vector targeting. We previously reported a gene delivery system based on a fiber gene-deleted Ad type 5 (Ad5) vector (Ad5.betagal.DeltaF) and packaging cells that express the viral fiber protein. Expression of different fibers in packaging cells will allow Ad retargeting without modifying the viral chromosome. Importantly, fiber proteins which can no longer bind to the producer cells can also be used. Using this approach, we generated for the first time pseudotyped Ad5.betagal.DeltaF particles containing either the wild-type Ad5 fiber protein or a chimeric fiber with the receptor-binding knob domain of the Ad3 fiber. Particles equipped with the chimeric fiber bound to the Ad3 receptor rather than the coxsackievirus-adenovirus receptor protein used by Ad5. EBV-transformed B lymphocytes were infected efficiently by the Ad3-pseudotyped particles but poorly by virus containing the Ad5 fiber protein. The strategy described here represents a broadly applicable method for targeting gene delivery to specific cell types.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10590124      PMCID: PMC111546          DOI: 10.1128/jvi.74.1.354-362.2000

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  59 in total

1.  Growth arrest of Epstein-Barr virus immortalized B lymphocytes by adenovirus-delivered ribozymes.

Authors:  S Huang; D Stupack; P Mathias; Y Wang; G Nemerow
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-22       Impact factor: 11.205

Review 2.  New perspectives in adenoviruses.

Authors:  S A Lukashok; M S Horwitz
Journal:  Curr Clin Top Infect Dis       Date:  1998

3.  Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers.

Authors:  K Jooss; Y Yang; K J Fisher; J M Wilson
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

4.  Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob.

Authors:  V Krasnykh; I Dmitriev; G Mikheeva; C R Miller; N Belousova; D T Curiel
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

5.  Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins.

Authors:  T J Wickham; E Tzeng; L L Shears; P W Roelvink; Y Li; G M Lee; D E Brough; A Lizonova; I Kovesdi
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  The coxsackievirus-adenovirus receptor protein can function as a cellular attachment protein for adenovirus serotypes from subgroups A, C, D, E, and F.

Authors:  P W Roelvink; A Lizonova; J G Lee; Y Li; J M Bergelson; R W Finberg; D E Brough; I Kovesdi; T J Wickham
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

7.  The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery.

Authors:  S J Watkins; V V Mesyanzhinov; L P Kurochkina; R E Hawkins
Journal:  Gene Ther       Date:  1997-10       Impact factor: 5.250

8.  Gene therapy strategies for treating Epstein-Barr virus-associated lymphomas: comparison of two different Epstein-Barr virus-based vectors.

Authors:  S Kenney; J Q Ge; E M Westphal; J Olsen
Journal:  Hum Gene Ther       Date:  1998-05-20       Impact factor: 5.695

9.  Adenoviral-mediated gene transfer in lymphocytes.

Authors:  R P Leon; T Hedlund; S J Meech; S Li; J Schaack; S P Hunger; R C Duke; J DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

10.  Complementation of a fibre mutant adenovirus by packaging cell lines stably expressing the adenovirus type 5 fibre protein.

Authors:  D J Von Seggern; J Kehler; R I Endo; G R Nemerow
Journal:  J Gen Virol       Date:  1998-06       Impact factor: 3.891

View more
  36 in total

1.  Adenovirus serotype 7 retention in a late endosomal compartment prior to cytosol escape is modulated by fiber protein.

Authors:  N Miyazawa; R G Crystal; P L Leopold
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

Review 2.  The promise and potential hazards of adenovirus gene therapy.

Authors:  L S Young; V Mautner
Journal:  Gut       Date:  2001-05       Impact factor: 23.059

3.  Targeting of adenovirus via genetic modification of the viral capsid combined with a protein bridge.

Authors:  Nikolay Korokhov; Galina Mikheeva; Alexander Krendelshchikov; Natalya Belousova; Vera Simonenko; Valentina Krendelshchikova; Alexander Pereboev; Alexander Kotov; Olga Kotova; Pierre L Triozzi; Wayne A Aldrich; Joanne T Douglas; Kin-Ming Lo; Papia T Banerjee; Stephen D Gillies; David T Curiel; Victor Krasnykh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

4.  Flexibility of the adenovirus fiber is required for efficient receptor interaction.

Authors:  Eugene Wu; Lars Pache; Dan J Von Seggern; Tina-Marie Mullen; Yeshi Mikyas; Phoebe L Stewart; Glen R Nemerow
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

5.  A chimeric adenovirus vector encoding reovirus attachment protein sigma1 targets cells expressing junctional adhesion molecule 1.

Authors:  George T Mercier; Jacquelyn A Campbell; James D Chappell; Thilo Stehle; Terence S Dermody; Michael A Barry
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

6.  Fiber and penton base capsid modifications yield diminished adenovirus type 5 transduction and proinflammatory gene expression with retention of antigen-specific humoral immunity.

Authors:  John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2006-08-30       Impact factor: 5.103

7.  Antiviral cyclic D,L-alpha-peptides: targeting a general biochemical pathway in virus infections.

Authors:  W Seth Horne; Christopher M Wiethoff; Chunli Cui; Keith M Wilcoxen; Manuel Amorin; M Reza Ghadiri; Glen R Nemerow
Journal:  Bioorg Med Chem       Date:  2005-09-01       Impact factor: 3.641

8.  Tropism modification of adenovirus vectors by peptide ligand insertion into various positions of the adenovirus serotype 41 short-fiber knob domain.

Authors:  Andrea Hesse; Daniela Kosmides; Roland E Kontermann; Dirk M Nettelbeck
Journal:  J Virol       Date:  2006-12-27       Impact factor: 5.103

Review 9.  Transductional targeting of adenovirus vectors for gene therapy.

Authors:  J N Glasgow; M Everts; D T Curiel
Journal:  Cancer Gene Ther       Date:  2006-01-27       Impact factor: 5.987

10.  Modification of adenovirus capsid with a designed protein ligand yields a gene vector targeted to a major molecular marker of cancer.

Authors:  Natalya Belousova; Galina Mikheeva; Juri Gelovani; Victor Krasnykh
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.